Quarterly ResultsCreated 10 August 20261 min read

CORONA Remedies Posts Strong Growth, Profitability Expands

The pharmaceutical firm reported robust year-on-year and sequential growth in both revenue and profit for the June quarter.

By Abhinav Singhvi, Founder & CEO Hexawealth

CORONA Remedies delivered a strong Q1 FY27, with revenue rising 21.9% and profit surging 30.1% year-on-year. Profit growth outpaced sales, lifting the net profit margin.

CORONA Remedies kicked off the new fiscal year with a strong quarter, posting double-digit growth in both revenue and profit. The company's performance was driven by a significant sequential uptick, indicating robust operating momentum as it entered FY27.

Revenue for Q1 FY27 came in at ₹422.43 crore, a 21.9% increase from the same quarter last year. Profit after tax grew even faster, rising 30.1% year-on-year to ₹60.11 crore. This profit growth outpacing sales lifted the net profit margin by 90 basis points to 14.2%, showcasing improved profitability.

The quarter also marked a sharp improvement from the preceding three months. Sequentially, revenue grew 19.6% from Q4 FY26, while profit jumped 32.6%. The recent quarterly performance is detailed below.

Revenue (₹ Cr)

Profit (₹ Cr)

Net Profit Margin

Metric	CurrentQ1 FY27	PreviousQ4 FY26	Same quarter LYQ1 FY26
Period	Quarter ended June 2026	Quarter ended March 2026	Quarter ended June 2025
Revenue (₹ Cr)	422.43YoY +22%	353.09	346.54
Profit (₹ Cr)	60.11YoY +30%	45.33	46.20
Net Profit Margin	14.2%YoY +6.8%	12.8%	13.3%

Key Points

The trailing twelve-month (TTM) net profit margin stands at 13.5%, with TTM profit at ₹199.03 crore.
The company maintains a strong balance sheet with a high return on equity of 27.36% and a comfortable debt-to-equity ratio of 0.19.
At a price-to-earnings (P/E) ratio of 51.4, the stock trades at a 38.4% premium to its industry average.

Overall, the quarter reflects healthy operational execution. The key question is whether the company can sustain this elevated level of profitability and growth in the coming quarters.

Live Chart

· CORONA

(BSE)

ISIN: INE02ZQ01018

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Corporate Address

T-Hub Phase 2, 6th Floor, 20, Inorbit Mall Rd, Vittal Rao Nagar, Madhapur, Hyderabad, Telangana 500081

SEBI Chennai Office: 7th Floor, 756-L, Anna Salai, Chennai - 600002, Tamil Nadu Tel. Board: +91-44- 28880222 / 28526686 Fax : +91-44 -28880333 E-mail : sebisro@sebi.gov.in

Investment in the securities market are subject to market risks. Read all the related documents carefully before investing. Your relationship with the Company will be governed by the Investment Advisory Agreement signed with you and the terms of use of this site. The Investment Adviser shall not incur any liability by reason of any loss, which a client may suffer by reason of any depletion in the value of the assets under advice, which may result by reason of fluctuation in asset value, or by reason of non-performance or under-performance of the securities/funds or any other market conditions.

HexaWealth is a brand name owned and operated by HEXAWEALTH FINANCIAL TECHNOLOGIES PRIVATE LIMITED, a SEBI-registered Investment Adviser (Registration No: INA000019080). Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance or returns. Investments are subject to market risks, read all related documents carefully

In terms of the regulatory requirements, you as a user can either avail our investment advisory services or distribution/facilitation services and not both. The Company shall make all endeavours to ensure segregation of the advisory and distribution activities by not offering both to the same user by placing appropriate post-login disablement/accessibility blocking checks on the website.